LIMN Liminatus Pharma, Inc.

CIK 0001971387 19 ready 8-Ks latest June 3, 2026, 5:14 PM ET RSS · JSON

Activity: ELEVATED 3 filings / 30d vs 1 baseline Risk accumulating: compliance/delisting (1)

Ready 8-Ks 19

Latest filing June 3, 2026, 5:14 PM ET

Top materiality 0.90

Event mix other_material ×8 · m_and_a ×4 · regulatory ×4

Sentiment 6 pos · 4 neg · 9 neu

Recent 8-K filings for LIMN

Highest-materiality recent filing

Liminatus Pharma completes de-SPAC merger, receives $15M PIPE, begins Nasdaq trading

May 6, 2025, 7:59 PM ET M&A materiality 0.90 positive item 1.01 item 2.01 item 5.02 item 3.02 item 4.01 item 9.01 item 3.03 item 5.01 item 5.03 item 5.05 item 5.06 item 7.01 item 8.01

Closed de-SPAC merger with Iris Acquisition Corp; issued 17.5M shares at $10/share ($175M equity value) to Liminatus securityholders.
Concurrent $15M PIPE investment (1.5M shares at $10) from accredited investor.

Read filing →

June 3, 2026, 5:14 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 3.03 item 8.01 item 9.01 ◈ Material Agreements

Liminatus Pharma raises $1.86M via warrant exercise inducement, issues new warrants for 20.7M shares

Gross proceeds of ~$1.86M from exercise of 10.344M existing warrants at reduced exercise price of $0.18 per share.
May 27, 2026, 4:30 PM ET other material materiality 0.85 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

Liminatus Pharma receives Nasdaq delisting notice; appeals filed

On May 20, 2026, Nasdaq notified Liminatus Pharma it failed to regain compliance with $50M MVLS and $15M MVPHS requirements.
May 20, 2026, 5:00 PM ET M&A materiality 0.75 neutral item 1.01 item 9.01

Liminatus Pharma to acquire InnocsAI in stock merger valued at ~$320M

1.6B shares at $0.20/share ($320M aggregate) plus contingent value rights of 20% of future net proceeds from asset sale.
March 4, 2026, 6:59 PM ET other materiality 0.10 neutral item 5.03 item 9.01 ◈ Governance Changes

Liminatus Pharma reduces stockholder quorum requirement from majority to one-third

Board approved bylaw amendment reducing quorum from majority to one-third of voting power.
February 18, 2026, 6:59 PM ET other material materiality 0.50 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Liminatus Pharma prices $4.0M public offering of common stock and warrants

Offering of 13.8M shares/pre-funded warrants and warrants for up to 20.7M shares at combined $0.29 per unit.
February 9, 2026, 6:59 PM ET litigation materiality 0.70 neutral item 1.01 item 3.02 item 9.01 ◈ Material Agreements

Liminatus Pharma issues 4M shares to settle $7.5M default judgment, dismisses lawsuits

Issued 4,000,000 shares to Clear Street LLC in exchange for surrender of 805,377 warrants.
January 26, 2026, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

Liminatus Pharma receives Nasdaq bid price deficiency notice; 180 days to regain compliance

Received Nasdaq deficiency notice on Jan 15, 2026 for failing to maintain $1 minimum bid price for 30 consecutive business days.
November 25, 2025, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

Liminatus Pharma receives Nasdaq delisting notices for failing MVLS and MVPHS rules

Notices dated Nov 19, 2025: MVLS below $50M and MVPHS below $15M for 30 consecutive business days.
August 25, 2025, 7:59 PM ET regulatory materiality 0.55 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

Liminatus Pharma receives Nasdaq delinquency notice for late Q2 10-Q filing; has 60 days to submit compliance plan

Nasdaq notified Liminatus on Aug 22, 2025 of non-compliance with Listing Rule 5250(c)(1) due to delayed Form 10-Q for period ended June 30, 2025.
August 14, 2025, 7:59 PM ET other material materiality 0.40 positive item 7.01 item 9.01

Liminatus Pharma provides IBA101 strategic update targeting PD-1/L1 patent cliff partnership opportunities

IBA101 is a CD47 mAb designed to avoid RBC/platelet binding, eliminating cytopenia that derailed Hu5F9 and lemzoparlimab.
July 17, 2025, 7:59 PM ET other material materiality 0.65 positive item 1.01 item 3.02 item 9.01

Liminatus Pharma exchanges 1M warrants for 350K shares with Alta Partners

Company issued 350,000 shares of common stock to Alta Partners in exchange for surrender and cancellation of 1,000,000 warrants.
July 11, 2025, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 item 9.01

Liminatus Pharma appoints Philip Lemons and Richard Baek to Board of Directors

Board expanded from 5 to 6 members with appointment of Lemons and Baek effective July 10, 2025.
July 3, 2025, 7:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Liminatus Pharma forms consortium for pancreatic cancer blood diagnostic with >95% sensitivity

Signed MOU with Samda Biolab and INNOCS AI to develop a blood-based diagnostic kit for early pancreatic cancer detection.
June 24, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Liminatus Pharma provides update on lead asset IBA101; IND filing H2 2025

IBA101 is a next-generation CD47 blockade designed to avoid anemia and thrombocytopenia seen with first-generation drugs.
June 24, 2025, 7:59 PM ET other material materiality 0.50 positive item 7.01 item 9.01

Liminatus Pharma advances IBA101 CD47 inhibitor toward IND submissions in H2 2026

Completed GLP toxicology studies at Charles River; no clinically meaningful hemoglobin or platelet reductions in primates.
June 4, 2025, 7:59 PM ET regulatory materiality 0.45 neutral item 3.01 item 9.01 ◈ Listing & Compliance Notices

Liminatus Pharma receives and resolves Nasdaq non-compliance for late 10-Q filing

Received Nasdaq notice on May 29, 2025, for non-compliance with Listing Rule 5250(c)(1) due to delayed Form 10-Q.
June 2, 2025, 7:59 PM ET M&A materiality 0.75 neutral item 2.01 item 9.01 item 1.01 item 5.02 item 3.02 item 4.01

Liminatus Pharma completes de-SPAC business combination, files Q1 2025 financials

Business combination closed April 30, 2025; combined company trades on Nasdaq as LIMN and LIMNW.
May 6, 2025, 7:59 PM ET M&A materiality 0.90 positive item 1.01 item 2.01 item 5.02 item 3.02 item 4.01 item 9.01 item 3.03 item 5.01 item 5.03 item 5.05 item 5.06 item 7.01 item 8.01

Liminatus Pharma completes de-SPAC merger, receives $15M PIPE, begins Nasdaq trading

Closed de-SPAC merger with Iris Acquisition Corp; issued 17.5M shares at $10/share ($175M equity value) to Liminatus securityholders.
April 30, 2025, 7:59 PM ET M&A materiality 0.80 positive item 9.01

Liminatus Pharma completes business combination with Iris Acquisition Corp; trades as LIMN

Combined company Liminatus Pharma, Inc. begins trading on Nasdaq under LIMN and LIMNW on May 1, 2025.

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

6 positive 4 negative 9 neutral

source · LIMN on sec.gov